Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
about
Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and chinaStrategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantationGla-rich protein is a potential new vitamin K target in cancer: evidences for a direct GRP-mineral interaction.Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma.The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinomaAlpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again.Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma.The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011.PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients.Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma.Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma.Des-gamma-carboxy prothrombin in hepatocellular cancer patients waiting for liver transplant: a systematic review and meta-analysis.Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma.Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection.Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics.Menahydroquinone-4 Prodrug: A Promising Candidate Anti-Hepatocellular Carcinoma Agent.Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: a meta-analysis based on 24 articles.Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma.Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.Biomarkers for hepatocellular carcinoma.New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma.
P2860
Q27003291-B35C0A8C-AD4C-41DB-803B-6E19EF30E9FEQ27005375-2C08C190-F27F-4B28-82E4-9AF070E3641CQ33737404-1C977561-797B-4764-B4EA-04AEC82B6A29Q35147875-ADD43C88-8277-48D9-A37D-D14B10DE219FQ35151800-4B65746B-DAAD-43A5-BA94-FED555322D39Q35270302-E06F5E24-5778-488B-B974-05F73AC19561Q36082480-A1761006-6AEC-45A2-AE5B-044E483E2B6BQ37122823-B5401404-F8EE-449E-AF18-38D5F00045BCQ37206392-BE5AFE8A-485A-44DE-B280-E77BA79C5AEDQ37995237-43C74911-84C4-456D-87A1-C4D01B2818C4Q38704682-96F695D9-748A-4924-8319-4F5F0816EBB8Q38849845-9F723CE9-1228-4E57-B006-DE1CC618AD72Q38965626-FE841A25-BE1B-4026-A145-D08A7138B6A3Q39340586-49220CDC-97F4-4C59-B131-2D6A79034E85Q39648514-33FFAAA3-A89D-4EB2-B8AA-35FB3B020898Q40065752-57834DC0-9013-4B71-96BF-09C73FD8CD1DQ40157126-BC7A28C3-626E-4B66-A638-0F847804E135Q41667581-05144778-9DDD-404A-81ED-873981814D0BQ41859517-DF675D2F-6882-4ED6-A6E0-4E947D365DC9Q41924403-24D82C9C-4D3D-4B95-9C6E-8FA1C61D6EA5Q42343446-BEB86BFE-94E3-4877-86C0-4A787338B7D8Q42371643-A5DD09EE-5AC4-414C-BF6A-8DCBAF3AF15DQ47142488-A063DFD0-6F5F-407A-BAE8-4EBF8E042B4EQ47649573-F1C98CFB-F81B-431D-8D7E-97D3CFD7CB3EQ47911866-0B187F62-1201-47EB-AC1F-FACF912DFA70Q51595454-86763749-7902-4DE7-9230-C0C4DE979DE3Q53084104-7C1687A4-66D6-4C0A-9FCB-67DAA0AF76EF
P2860
Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical and molecular insight ...... rker des-γ-carboxyprothrombin.
@en
Clinical and molecular insight ...... rker des-γ-carboxyprothrombin.
@nl
type
label
Clinical and molecular insight ...... rker des-γ-carboxyprothrombin.
@en
Clinical and molecular insight ...... rker des-γ-carboxyprothrombin.
@nl
prefLabel
Clinical and molecular insight ...... rker des-γ-carboxyprothrombin.
@en
Clinical and molecular insight ...... rker des-γ-carboxyprothrombin.
@nl
P50
P1433
P1476
Clinical and molecular insight ...... rker des-γ-carboxyprothrombin.
@en
P2093
P2860
P356
10.1111/J.1478-3231.2010.02348.X
P577
2010-09-27T00:00:00Z